this May. “And so, we're trying to automate out some of the steps that might lead to bottlenecks and longer timelines in both construct design for manufacturing and data analysis.”
“The way that we like to think about Form Bio is that it's a platform to enable synthetic biology,” explains Stearn. “Typical synbio organizations have heavy R&D investment on the science side of things, but the data science side might be under-resourced. Our platform is a one-stop shop for all things data management, visualization, analysis, workflows, and collaboration.”
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: